Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The Company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)